Multiple myeloma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BCMA 134
• CD38 22
• GPRC5D 36
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 4
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• AMPK 0
• B7-H3 0
• NRAS 1
• TIGIT 0
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

EU-13 is a filter, not a ranking: it only narrows the list.

20 of 20+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

  NCT05513612· Shanghai Pudong Hospital· Updated 1 Mar 2023

  “The study is not initiated and we want it to be withdrawn.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

  NCT07735637· AstraZeneca· Source

• A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.

  2026-525367-40-00· AstraZeneca AB· Source

• AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  NCT05850234· AstraZeneca· Source

• A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· AstraZeneca· Source

• A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

  NCT07073547· AstraZeneca· Source

• A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma

  2025-524014-29-00· AstraZeneca AB· Source

• Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· AstraZeneca· Source

• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.

  2025-523285-25-00· AstraZeneca AB· Source

• A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

  NCT06235229· Gracell Biotechnologies (Shanghai) Co., Ltd.· Source

• Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

  NCT07139509· Xi'an No.3 Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 17
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

• Light Chain Crystalline Proximal Tubulopathy and Podocytopathy With Staining for Both Light and Heavy Chain Immunoglobulin.

  Nephrology (Carlton), Aug 2026

• Clinicopathologic characterization of plasma cell neoplasms with IGH::CCND3.

  Am J Clin Pathol, Jul 2026

• [Diagnostic value of minimal endometrial sampling combined with CD138+MUM-1 dual immunostaining for chronic endometritis in FET cycles: a propensity score matching retrospective cohort study].

  Zhonghua Fu Chan Ke Za Zhi, Jun 2026

• Multifocal non-epitheliotrophic cutaneous B-cell Lymphoma in a dog: cytologic, histopathologic, immunophenotypic, and molecular findings.

  BMC Vet Res, Jun 2026

• Validation of a QuPath-Based Artificial Intelligence Workflow for Plasma Cell Quantification on CD138 Immunohistochemistry in an Indian Hematopathology Cohort.

  Clin Lymphoma Myeloma Leuk, Jun 2026

• Multiple Myeloma Concomitant with AL Amyloidosis: Histopathological Aspects of the Common Plasma Cell Spectrum.

  Int J Mol Sci, Jun 2026

• CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma.

  Am J Clin Pathol, Jun 2026

• The diagnostic utility and frequency of CD56 expression in plasma cell myeloma.

  Ann Diagn Pathol, Nov 2025

• The Association and Significance of MDM2 and NF-κB Protein Expression in Multiple Myeloma.

  Medicina (Kaunas), Oct 2025

• Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.

  Oncotarget, Feb 2017

See which targets of this disease your abstract mentions, and go to the people working on them.